azathioprine has been researched along with Arthritis in 74 studies
Azathioprine: An immunosuppressive agent used in combination with cyclophosphamide and hydroxychloroquine in the treatment of rheumatoid arthritis. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance has been listed as a known carcinogen. (Merck Index, 11th ed)
azathioprine : A thiopurine that is 6-mercaptopurine in which the mercapto hydrogen is replaced by a 1-methyl-4-nitroimidazol-5-yl group. It is a prodrug for mercaptopurine and is used as an immunosuppressant, prescribed for the treatment of inflammatory conditions and after organ transplantation and also for treatment of Crohn's didease and MS.
Arthritis: Acute or chronic inflammation of JOINTS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Severe pancytopenia due to azathioprine (AZA) toxicity in patients with autoimmune diseases is not uncommon." | 7.69 | Azathioprine-induced severe pancytopenia due to a homozygous two-point mutation of the thiopurine methyltransferase gene in a patient with juvenile HLA-B27-associated spondylarthritis. ( Haas, JP; Leipold, G; Oellerich, M; Schütz, E, 1997) |
| "Leflunomide is a new immunosuppressive drug recently introduced in the treatment of rheumatoid and psoriatic arthritis." | 5.33 | Anti-Jo-1 antibody positive polymyositis--successful therapy with leflunomide. ( Lange, U; Müller-Ladner, U; Piegsa, M; Strunk, J, 2006) |
| " Renewed remission was obtained with additional infliximab, and was maintained with azathioprine for 12 months before the patient again presented with symmetrical polyarthritis." | 3.73 | [Symmetric polyarthritis in a patient with Churg-Strauss syndrome]. ( Aries, PM; Reinhold-Keller, E, 2005) |
| "In an open-label study, 6 patients with moderately active SLE (4 with nephritis and 3 with arthritis refractory to other therapies) were given 4 300-mg doses of infliximab, a chimeric anti-TNFalpha antibody, in addition to immunosuppression with azathioprine or methotrexate." | 3.72 | Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. ( Aringer, M; Graninger, WB; Smolen, JS; Steiner, G, 2004) |
| "We present a 28-year-old patient with liquefying idiopathic lobular panniculitis, a variant of the Weber-Christian's disease and intermittent episodes of arthritis in the left foot refractory to sequential treatment with anti-inflammatory drugs, high doses of prednisone, chloroquine, dapsone, colchicine, cyclosporine and methotrexate." | 3.69 | [Refractory idiopathic liquefying panniculitis]. ( Antón Badiola, I; Ferreiro Seoane, JL; Formigo Rodríguez, E; Gómez Rodríguez, N, 1995) |
| "Severe pancytopenia due to azathioprine (AZA) toxicity in patients with autoimmune diseases is not uncommon." | 3.69 | Azathioprine-induced severe pancytopenia due to a homozygous two-point mutation of the thiopurine methyltransferase gene in a patient with juvenile HLA-B27-associated spondylarthritis. ( Haas, JP; Leipold, G; Oellerich, M; Schütz, E, 1997) |
| "Arthritis in systemic lupus erythematosus (SLE) is episodic and self-limited in most patients." | 2.48 | How to treat refractory arthritis in lupus? ( Artifoni, M; Puéchal, X, 2012) |
| "Crohn's disease is a perplexing disease with a high rate of morbidity and complications." | 2.35 | The protean manifestations of Crohn's disease. ( Farmer, RG, 1975) |
| "It is important to distinguish between ulcerative colitis and Crohn's colitis because response to treatment and prognosis are different." | 2.35 | Inflammatory disease of the colon: ulcerative colitis and Crohn's colitis. ( Ament, ME, 1975) |
| "As sarcoidosis is a mimicking disease, a good differential diagnosis should be made to avoid misdiagnosis and in order not to be late in diagnosis and treatment." | 1.72 | Perspective of sarcoidosis in terms of rheumatology: a single-center rheumatology clinic experience. ( Duruöz, MT; Esen, İ; Gezer, HH; Karabulut, Y; Öz, N, 2022) |
| "Idiopathic granulomatous mastitis is an inflammatory mass in the breast." | 1.37 | A case of granulomatous mastitis with erythema nodosum and arthritis. ( Karimifar, M; Mahzouni, P; Salesi, M; Salimi, F, 2011) |
| "A 36-year-old woman with systemic lupus erythematosus was admitted to our hospital with malaise, myalgia, dysphagia, fever, preserved muscle strength, leukocytosis (15,600 cells), and increased creatine kinase of 1,358 IU/L that reached 75,000 IU/L in few days." | 1.37 | Fatal rhabdomyolysis in systemic lupus erythematosus. ( Bonfa, E; da Mota, LM; de Carvalho, JF, 2011) |
| "CINCA syndrome is a genetic disorder characterized by early onset of recurrent fever, rash, progressive articular and neurological involvement." | 1.34 | CINCA Syndrome. ( Khemani, C; Khubchandani, R, 2007) |
| "Leflunomide is a new immunosuppressive drug recently introduced in the treatment of rheumatoid and psoriatic arthritis." | 1.33 | Anti-Jo-1 antibody positive polymyositis--successful therapy with leflunomide. ( Lange, U; Müller-Ladner, U; Piegsa, M; Strunk, J, 2006) |
| "A 52-year-old woman with a history of chronic obstructive pulmonary disease presented with symmetrical polyarthritis involving her metacarpophalangeal and proximal interphalangeal joints, knees, ankles, and hips and with a purpuric rash involving her lower extremities." | 1.32 | Churg-Strauss syndrome: diagnostic difficulties and pathogenesis. ( Buscemi, DM; Diri, E; Nugent, KM, 2003) |
| " During gradual reduction of the steroid dosage osteocalcin returned to pretreatment values." | 1.27 | Serum osteocalcin in rheumatoid arthritis and other inflammatory arthritides: relation between inflammatory activity and the effect of glucocorticoids and remission inducing drugs. ( Ekenstam, EA; Hällgren, R; Ljunghall, S, 1986) |
| "The influence of adjuvant arthritis in rats on main urinary metabolites (MUM) of prostaglandin (PG) F and E type was studied." | 1.26 | Influence of adjuvant arthritis on main urinary metabolites of prostaglandin F and E in rats. ( Fukawa, K; Honda, H; Sawabe, T, 1980) |
| "Of these dogs, 29 had systemic lupus erythematosus, 15 had arthritis in association with some chronic infectious disease process, and 19 had a similar type of arthritis, but without serologic evidence of systemic lupus erythematosus or any chronic infectious disease process." | 1.26 | Noninfectious canine arthritis: the inflammatory, nonerosive arthritides. ( Castles, JJ; Ling, GV; Pedersen, NC; Weiser, G; Weisner, K, 1976) |
| "A modified model of adjuvant arthritis is described that permits simultaneous quantitative measurement of the humoral and the cellular immune response to a secondary immunogen (el4 cells) in the arthritic rat." | 1.26 | Adjuvant polyarthritis I: incorporation of quantitative measurements of humoral and cellular immune response. ( Chang, YH, 1977) |
| "Treatment with azathioprine resulted in a progressive improvement in her condition." | 1.26 | A case of pulmonary veno-occlusive disease respondong to treatment with azathioprine. ( Hendry, AT; Sanderson, JE; Spiro, SG; Turner-Warwick, M, 1977) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 47 (63.51) | 18.7374 |
| 1990's | 5 (6.76) | 18.2507 |
| 2000's | 11 (14.86) | 29.6817 |
| 2010's | 9 (12.16) | 24.3611 |
| 2020's | 2 (2.70) | 2.80 |
| Authors | Studies |
|---|---|
| Lanis, A | 1 |
| Volochayev, R | 1 |
| Kleiner, DE | 1 |
| Vittal, A | 1 |
| Heller, T | 1 |
| Rider, LG | 1 |
| Shenoi, S | 1 |
| Karabulut, Y | 1 |
| Öz, N | 1 |
| Gezer, HH | 1 |
| Esen, İ | 1 |
| Duruöz, MT | 1 |
| Parlow, B | 1 |
| Mohiuddin, A | 1 |
| Chou, T | 1 |
| Cato-Varlack, J | 1 |
| Boneparth, A | 1 |
| Moorthy, LN | 1 |
| Bowling, MR | 1 |
| Cauthen, CG | 1 |
| Perry, CD | 1 |
| Patel, NP | 1 |
| Bergman, S | 1 |
| Link, KM | 1 |
| Sane, AC | 1 |
| Conforti, JF | 1 |
| Sahin, G | 1 |
| Korkmaz, C | 2 |
| Işiksoy, S | 1 |
| Yalçin, AU | 1 |
| Telles, RW | 1 |
| Ferreira, GA | 1 |
| da Silva, NP | 1 |
| Sato, EI | 1 |
| Salesi, M | 1 |
| Karimifar, M | 1 |
| Salimi, F | 1 |
| Mahzouni, P | 1 |
| Donghi, D | 1 |
| Mainetti, C | 1 |
| Gelber, AC | 1 |
| Jackson, TE | 1 |
| Pathak, S | 1 |
| Doran, RM | 1 |
| de Carvalho, JF | 1 |
| da Mota, LM | 1 |
| Bonfa, E | 1 |
| Artifoni, M | 1 |
| Puéchal, X | 1 |
| Diri, E | 1 |
| Buscemi, DM | 1 |
| Nugent, KM | 1 |
| Aringer, M | 1 |
| Graninger, WB | 1 |
| Steiner, G | 1 |
| Smolen, JS | 1 |
| Aries, PM | 1 |
| Reinhold-Keller, E | 1 |
| Demirtaş-Ertan, G | 1 |
| Rowshani, AT | 1 |
| ten Berge, IJ | 1 |
| Lange, U | 1 |
| Piegsa, M | 1 |
| Müller-Ladner, U | 1 |
| Strunk, J | 1 |
| Gündüz, E | 1 |
| Kaşifoğlu, T | 1 |
| Gülbaş, Z | 1 |
| Khemani, C | 1 |
| Khubchandani, R | 1 |
| Lloyd, A | 1 |
| Kemball, M | 1 |
| Fraser, G | 1 |
| Guillen, C | 1 |
| Fortea, JM | 1 |
| Serrano, G | 1 |
| Martorell, MA | 1 |
| Cogollos, E | 1 |
| Alegre, V | 1 |
| Aliaga, A | 1 |
| Huskisson, EC | 1 |
| Sibiriak, SV | 1 |
| Lazareva, DN | 1 |
| Kokhanchikova, NA | 1 |
| Davies, PG | 1 |
| Fordham, JN | 1 |
| Jones, JV | 1 |
| Robinson, MF | 1 |
| Parciany, RK | 1 |
| Layfer, LF | 1 |
| McLeod, B | 1 |
| Honda, H | 1 |
| Fukawa, K | 1 |
| Sawabe, T | 1 |
| Pillans, PI | 1 |
| Tooke, AF | 1 |
| Bateman, ED | 1 |
| Ainslie, GM | 1 |
| Gómez Rodríguez, N | 1 |
| Formigo Rodríguez, E | 1 |
| Ferreiro Seoane, JL | 1 |
| Antón Badiola, I | 1 |
| Felchle, LM | 1 |
| McPhee, LA | 1 |
| Kerr, ME | 1 |
| Houston, DM | 1 |
| Leipold, G | 1 |
| Schütz, E | 1 |
| Haas, JP | 1 |
| Oellerich, M | 1 |
| Burmester, GR | 1 |
| Feist, E | 1 |
| Krause, A | 1 |
| Elston, DM | 1 |
| Cacoub, P | 1 |
| Sbaï, A | 1 |
| Toan, SV | 1 |
| Bellanger, J | 1 |
| Hoang, C | 1 |
| Godeau, P | 1 |
| Piette, JC | 1 |
| Russo, RA | 1 |
| Katsicas, MM | 1 |
| Pedersen, NC | 1 |
| Weisner, K | 1 |
| Castles, JJ | 1 |
| Ling, GV | 1 |
| Weiser, G | 1 |
| Thumb, N | 1 |
| Grabner, H | 1 |
| Gruber, F | 1 |
| Kolarz, G | 1 |
| Kasper, H | 1 |
| Farmer, RG | 1 |
| Ament, ME | 1 |
| Vinegar, R | 1 |
| Truax, JF | 1 |
| Selph, JL | 1 |
| Lea, A | 1 |
| Johnston, PR | 1 |
| Chang, YH | 1 |
| Sanderson, JE | 1 |
| Spiro, SG | 1 |
| Hendry, AT | 1 |
| Turner-Warwick, M | 1 |
| Feldges, DH | 2 |
| Barnes, CG | 2 |
| Prat, A | 1 |
| Gascon, J | 1 |
| Shorter, RG | 1 |
| Shephard, DA | 1 |
| Clements, PJ | 1 |
| Davis, J | 1 |
| Crossley, MJ | 1 |
| Spowage, M | 1 |
| Hunneyball, IM | 1 |
| Ekenstam, EA | 1 |
| Ljunghall, S | 1 |
| Hällgren, R | 2 |
| Kanezuka, T | 1 |
| Hatanaka, Y | 1 |
| Pavelka, K | 1 |
| Alusík, S | 1 |
| Lukás, K | 1 |
| Lukás, M | 1 |
| Mirejovský, P | 1 |
| Zloský, P | 1 |
| Brückle, W | 1 |
| Cochrane, D | 1 |
| Adamson, AR | 1 |
| Halsey, JP | 1 |
| Svenson, K | 1 |
| Johansson, E | 1 |
| Lindh, U | 1 |
| Rhodes, J | 1 |
| Bainton, D | 1 |
| Beck, P | 1 |
| Campbell, H | 1 |
| Fügner, A | 1 |
| Levy, L | 1 |
| Swannell, AJ | 1 |
| Coomes, EN | 1 |
| Villard, G | 1 |
| Delacretaz, J | 1 |
| Tsukada, W | 1 |
| Akimoto, T | 1 |
| Mizushima, Y | 1 |
| Fidler, JP | 1 |
| Alexander, JW | 1 |
| Smith, EJ | 1 |
| Miller, HC | 1 |
| Muthiah, V | 1 |
| Levy, J | 1 |
| Barnett, EV | 1 |
| MacDonald, NS | 1 |
| Klinenberg, JR | 1 |
| Pearson, CM | 1 |
| Jouanneau, M | 1 |
| Brouilhet, H | 1 |
| Kahan, A | 1 |
| Charles, A | 1 |
| Delbarre, F | 1 |
| Hershfield, NB | 1 |
| Suzuki, Y | 1 |
| Ito, I | 1 |
| Ito, M | 1 |
| Yamagami, I | 1 |
| Rothermich, NO | 1 |
| Arinoviche, R | 1 |
| Loewi, G | 1 |
| Grob, PJ | 1 |
| Arrigoni-Martelli, E | 1 |
| Schiatti, P | 1 |
| Selva, D | 1 |
| Heidelmann, G | 1 |
| Fleischer, J | 1 |
| Schwenke, R | 1 |
| Currey, HL | 1 |
| Klein, G | 1 |
| Becke, RF | 1 |
| Miehlke, K | 1 |
| Kohlhardt, J | 1 |
| Wirth, B | 1 |
| Kafarnik, U | 1 |
| Gross, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-Blind, Placebo-Controlled, Phase II, Multi-Center Study for Treatment of Lupus Nephritis by Inhibition of Tumor Necrosis Factor-alpha Using Etanercept[NCT00447265] | Phase 2 | 1 participants (Actual) | Interventional | 2008-02-29 | Terminated (stopped due to The perceived risk-benefit ratio for individuals with early active RA) | ||
| A Double Blind, Randomized, Placebo Controlled, Multi-Center Trial of Anti-TNF-alpha Chimeric Monoclonal Antibody (Infliximab) and Azathioprine in Patients Suffering From Systemic Lupus Erythematosus (SLE) With WHO Class V Glomerulonephritis[NCT00368264] | Phase 2/Phase 3 | 1 participants (Actual) | Interventional | 2006-09-30 | Terminated (stopped due to Failure to recruit patients with membranous lupus nephritis not previously treated with azathioprine .) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Number of adverse events (AEs) or serious adverse events (SAEs) Grade 3 or higher experienced by participant over the duration of the treatment period. [1]~[1] This study graded the severity of AEs experienced by the study participant according to the criteria set forth in the National Cancer Institute's Common Terminology Criteria for Adverse Events Version 3.0." (NCT00447265)
Timeframe: 24 Weeks
| Intervention | Events (Number) |
|---|---|
| Etanercept | 0 |
Number of participant AEs during the trial. This study graded the severity of AEs experienced by the study participant according to the criteria set forth in the National Cancer Institute's Common Terminology Criteria for Adverse Events Version 3.0. (NCT00447265)
Timeframe: 39 Weeks
| Intervention | Events (Number) |
|---|---|
| Etanercept | 3 |
Reported here is the number of participants with a change in their BILAG Musculoskeletal Score from B (at baseline) to D (at week 24). A single alphabetic score (A through E) is used to denote disease severity. The BILAG score is a converted numerical score (A=9, B=3, C=1, D=0, E=0).A maximum musculoskeletal score of 9 signifies higher disease activity and a score of 0 is indicative of inactive systematic lupus erythematosus (SLE) in the specified organ system. (NCT00447265)
Timeframe: Baseline, Week 24
| Intervention | Participants (Number) |
|---|---|
| Etanercept | 1 |
Reported here is the number of participants with a change in their BILAG Mucocutaneous Score from C (at baseline) to B (at week 24). A single alphabetic score (A through E) is used to denote disease severity. The BILAG score is a converted numerical score (A=9, B=3, C=1, D=0, E=0). A maximum mucocutaneous score of 9 signifies higher disease activity and a score of 0 is indicative of inactive systematic lupus erythematosus (SLE) in the specified organ system. (NCT00447265)
Timeframe: Baseline, Week 24
| Intervention | Participants (Number) |
|---|---|
| Etanercept | 1 |
Reported here is the number of participants with a change in their BILAG Renal Score from A (at baseline) to B (at week 24). A single alphabetic score (A through E) is used to denote disease severity. The BILAG score is a converted numerical score (A=9, B=3, C=1, D=0, E=0).A maximum renal score of 9 signifies higher disease activity and a score of 0 is indicative of inactive systematic lupus erythematosus (SLE) in the specified organ system (NCT00447265)
Timeframe: Baseline, Week 24
| Intervention | Participants (Number) |
|---|---|
| Etanercept | 1 |
"Percent of study participants who achieved a renal response at 24 weeks.[1]~[1]A renal response is defined as: 1) 50% reduction in proteinuria compared to baseline as measured by urinary protein: creatinine ratio; and 2) stable or improving renal function as defined by the Glomerular filtration rate (GFR) calculated based on the Modification of Diet in Renal Disease equation (Levy, AS, Coresh J, Galk E et al, National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med, 139(2): 137-47, 2003)" (NCT00447265)
Timeframe: Week 24
| Intervention | Percent of Participants (Number) |
|---|---|
| Etanercept | 100 |
"Time to when participant achieved a renal response[1]~[1]A renal response is defined as: 1) 50% reduction in proteinuria compared to baseline as measured by urinary protein: creatinine ratio; and 2) stable or improving renal function as defined by the Glomerular filtration rate (GFR) calculated based on the Modification of Diet in Renal Disease equation (Levy, AS, Coresh J, Galk E et al, National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med, 139(2): 137-47, 2003)" (NCT00447265)
Timeframe: First 24 Weeks of Study Period
| Intervention | Weeks (Number) |
|---|---|
| Etanercept | 24 |
"Reported here are the participant SF-36 Mental Component scores at baseline and week 24. The SF-36 measures 8 domains: physical functioning, role limitations due to physical health, bodily pain, social functioning, mental health, role limitations due to emotional problems, vitality, and general health perceptions.[1] The Mental Component score of the SF-36 ranges from 0 to 100; 0 equals worst health state. Higher numbers reported here indicate more improvement in condition from baseline.~[1]Ref: Ware JE, Sherbourne CD. The MOS36-item short-form health survey. Med Care. 1992; 30:473-483" (NCT00447265)
Timeframe: Baseline, Week 24
| Intervention | Score on a scale (Number) | |
|---|---|---|
| Baseline SF-36 Mental Component Score | Week 24 SF-36 Mental Component Score | |
| Etanercept | 31.4 | 52.3 |
"Reported here is the participant baseline and week 24 SF-36 Physical Component scores. The SF-36 measures 8 domains: physical functioning, role limitations due to physical health, body pain, social functioning, mental health, role limitations due to emotional problems, vitality, and general health perceptions[1]. The Physical Component scores of the SF-36 range from 0 to 100; 0 equals worst health state. Higher numbers reported here indicate more improvement in condition from baseline.~[1]Ref: Ware JE, Sherbourne CD. The MOS36-item short-form health survey Med Care. 1992; 30:473-483." (NCT00447265)
Timeframe: Baseline, Week 24
| Intervention | Score on a scale (Number) | |
|---|---|---|
| Baseline SF-36 Physical Component Score | Week 24 SF-36 Physical Component Score | |
| Etanercept | 44.4 | 42.3 |
Reported here is the baseline and week 39 Systematic Lupus Erythematosus Disease Activity Index (SLEDAI) scores. The SLEDAI is a concise measure of lupus disease activity with excellent test-retest reliability and high responsiveness to clinically important changes in the disease. The total score is derived from ratings on 24 conditions plus the Physician's Global Assessment; 0 indicates inactive disease and the maximum theoretical score is 105, with higher scores representing increased disease activity. (NCT00447265)
Timeframe: Baseline, Week 39 (Early Study Withdrawal Visit)
| Intervention | Points on a scale (Number) | |
|---|---|---|
| Baseline SLEDAI Score | Week 39 SLEDAI score | |
| Etanercept | 22 | 8 |
7 reviews available for azathioprine and Arthritis
| Article | Year |
|---|---|
How to treat refractory arthritis in lupus?
Topics: Abatacept; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal, | 2012 |
Acute polyarthritis associated with azathioprine for interstitial lung disease.
Topics: Acute Disease; Arthritis; Azathioprine; Drug Hypersensitivity; Drug Therapy, Combination; Female; Hu | 1995 |
The protean manifestations of Crohn's disease.
Topics: Adolescent; Adrenocorticotropic Hormone; Adult; Arthritis; Azathioprine; Child; Colectomy; Colitis, | 1975 |
Inflammatory disease of the colon: ulcerative colitis and Crohn's colitis.
Topics: Adrenal Cortex Hormones; Adult; Anus Diseases; Arthritis; Azathioprine; Child, Preschool; Colectomy; | 1975 |
Cytotoxic drugs: their clinical application to the rheumatic diseases.
Topics: Arthritis; Arthritis, Rheumatoid; Azathioprine; Behcet Syndrome; Bone Marrow; Cell Division; Chemica | 1986 |
An updated look at antirheumatic drugs.
Topics: Allopurinol; Anti-Inflammatory Agents; Arthritis; Azathioprine; Chloroquine; Cyclophosphamide; Gluco | 1967 |
[Current status of immunosuppressive therapy in non-neoplastic disorders].
Topics: Arthritis; Autoimmune Diseases; Azathioprine; Bone Marrow; Bone Marrow Diseases; Chemical Phenomena; | 1970 |
2 trials available for azathioprine and Arthritis
| Article | Year |
|---|---|
[Therapy evaluation in rheumatology with an electronic data processing system].
Topics: Anti-Inflammatory Agents; Arthritis; Azathioprine; Clinical Trials as Topic; Computers; Cyclophospha | 1976 |
Controlled trial of azathioprine in Crohn's disease.
Topics: Adolescent; Adult; Aged; Arthritis; Azathioprine; Clinical Trials as Topic; Crohn Disease; Double-Bl | 1971 |
65 other studies available for azathioprine and Arthritis
| Article | Year |
|---|---|
Nodular Regenerative Hyperplasia of the liver in Juvenile Dermatomyositis.
Topics: Abatacept; Adolescent; Arthritis; Autoantibodies; Azathioprine; Calcinosis; Child; Cyclophosphamide; | 2022 |
Perspective of sarcoidosis in terms of rheumatology: a single-center rheumatology clinic experience.
Topics: Adrenal Cortex Hormones; Ambulatory Care Facilities; Anti-Inflammatory Agents, Non-Steroidal; Arthri | 2022 |
Abdominal pain, rash, and arthritis.
Topics: Abdominal Pain; Adolescent; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis; Azathioprine; | 2015 |
Pulmonary extramedullary hematopoiesis.
Topics: Anemia, Hemolytic; Antirheumatic Agents; Arthritis; Azathioprine; Biopsy, Fine-Needle; Diagnosis, Di | 2008 |
Autoimmune hypothyroidism and lupus-like syndrome.
Topics: Adult; Arthritis; Azathioprine; Biphenyl Compounds; Complement C3; Complement C4; Complement System | 2010 |
Increased plasma myeloperoxidase levels in systemic lupus erythematosus.
Topics: Adult; Age of Onset; Antimalarials; Arthritis; Azathioprine; Biomarkers; Cross-Sectional Studies; Cy | 2010 |
A case of granulomatous mastitis with erythema nodosum and arthritis.
Topics: Antirheumatic Agents; Arthritis; Azathioprine; Colchicine; Drug Therapy, Combination; Erythema Nodos | 2011 |
Infliximab for the treatment of refractory Adamantiades-Behçet disease with articular, intestinal, cerebral and ocular involvement.
Topics: Adolescent; Antibodies, Monoclonal; Arthritis; Aspirin; Azathioprine; Behcet Syndrome; Chronic Disea | 2010 |
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal; Arthritis; Azathioprine; Crohn Disease; Drug Thera | 2010 |
Behçet disease presenting with frosted branch angiitis.
Topics: Arthritis; Azathioprine; Behcet Syndrome; Fundus Oculi; Hematocele; HLA-B Antigens; HLA-B51 Antigen; | 2011 |
Fatal rhabdomyolysis in systemic lupus erythematosus.
Topics: Acute Kidney Injury; Adult; Anti-Bacterial Agents; Antibodies, Antinuclear; Arthritis; Azathioprine; | 2011 |
Churg-Strauss syndrome: diagnostic difficulties and pathogenesis.
Topics: Antirheumatic Agents; Arthritis; Azathioprine; Churg-Strauss Syndrome; Female; Humans; Middle Aged; | 2003 |
Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study.
Topics: Adult; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis; Autoantibodies; Azathioprine; Bacter | 2004 |
Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study.
Topics: Adult; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis; Autoantibodies; Azathioprine; Bacter | 2004 |
Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study.
Topics: Adult; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis; Autoantibodies; Azathioprine; Bacter | 2004 |
Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study.
Topics: Adult; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis; Autoantibodies; Azathioprine; Bacter | 2004 |
[Symmetric polyarthritis in a patient with Churg-Strauss syndrome].
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis; Azathioprine; Churg-Strauss Syndrome; Cyclo | 2005 |
Azathioprine-induced shock in a patient suffering from undifferentiated erosive oligoarthritis.
Topics: Anaphylaxis; Antirheumatic Agents; Arthritis; Azathioprine; Humans; Immunosuppressive Agents; Male; | 2006 |
Anti-Jo-1 antibody positive polymyositis--successful therapy with leflunomide.
Topics: Antibodies, Antinuclear; Arthritis; Autoantibodies; Azathioprine; Drug Therapy, Combination; Female; | 2006 |
Unusual presentation of non-Hodgkin lymphoma: polyarthritis and uveitis mimicking a rheumatologic disease.
Topics: Arthritis; Arthritis, Rheumatoid; Azathioprine; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Middl | 2008 |
CINCA Syndrome.
Topics: Age Factors; Arthritis; Azathioprine; Carrier Proteins; Child; Chronic Disease; Erythema; Female; Fe | 2007 |
Peripheral gangrene in infancy and childhood.
Topics: Arthritis; Azathioprine; Child, Preschool; Female; Gangrene; Humans; Hyperbaric Oxygenation; Infant; | 1967 |
Multicentric reticulohistiocytosis.
Topics: Arthritis; Azathioprine; Humans; Lymphatic Diseases; Male; Middle Aged; Myositis; Skin Neoplasms | 1984 |
Azathioprine.
Topics: Arthritis; Arthritis, Rheumatoid; Azathioprine; Female; Gastrointestinal Diseases; Humans; Leukopeni | 1984 |
[Combined use of prodigiozan and methyluracil with immunosuppressive drugs in adjuvant arthritis in rats].
Topics: Animals; Arthritis; Arthritis, Experimental; Azathioprine; Cyclophosphamide; Drug Interactions; Drug | 1984 |
Arthritis and angioimmunoblastic lymphadenopathy.
Topics: Aged; Arthritis; Azathioprine; Female; Humans; Immunoblastic Lymphadenopathy; Lymph Nodes; Middle Ag | 1983 |
Therapeutic plasmapheresis in systemic lupus erythematosus. Effect on immune complexes and antibodies to DNA.
Topics: Adolescent; Adult; Antibodies, Antinuclear; Antigen-Antibody Complex; Arthritis; Azathioprine; Chlor | 1981 |
Influence of adjuvant arthritis on main urinary metabolites of prostaglandin F and E in rats.
Topics: Animals; Arthritis; Arthritis, Experimental; Azathioprine; Indomethacin; Male; Prednisolone; Prostag | 1980 |
[Refractory idiopathic liquefying panniculitis].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Azathioprine; Diclofenac; Drug Resistance | 1995 |
Systemic lupus erythematosus and bone marrow necrosis in a dog.
Topics: Animals; Anti-Inflammatory Agents; Antibodies, Antinuclear; Antirheumatic Agents; Arthritis; Azathio | 1996 |
Azathioprine-induced severe pancytopenia due to a homozygous two-point mutation of the thiopurine methyltransferase gene in a patient with juvenile HLA-B27-associated spondylarthritis.
Topics: Adolescent; Antirheumatic Agents; Arthritis; Azathioprine; Female; HLA-B27 Antigen; Homozygote; Huma | 1997 |
[Reactive arthritis. Diagnosis, differential diagnosis and therapy].
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Reactive; Arthritis, R | 1999 |
Photo quiz. Drug-induced pemphigus foliaceus.
Topics: Angiotensin-Converting Enzyme Inhibitors; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Stero | 2000 |
[Collagenous colitis. A study of 11 cases].
Topics: Adult; Agammaglobulinemia; Aged; Aged, 80 and over; Anemia; Anti-Inflammatory Agents; Anti-Inflammat | 2001 |
Chronic infantile neurological cutaneous and articular syndrome: two new cases with rare manifestations.
Topics: Abnormalities, Multiple; Antirheumatic Agents; Arthritis; Azathioprine; Child, Preschool; Chronic Di | 2001 |
Noninfectious canine arthritis: the inflammatory, nonerosive arthritides.
Topics: Animals; Arthritis; Arthritis, Infectious; Azathioprine; Cyclophosphamide; Dog Diseases; Dogs; Femal | 1976 |
[Enteritis regionalis (Crohn's disease) (proceedings)].
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Amyloidosis; Arthritis; Azathioprine; Child; Child | 1976 |
Azathioprine treatment of adjuvant arthritis.
Topics: Animals; Arthritis; Arthritis, Experimental; Azathioprine; Female; Mycobacterium; Rats | 1979 |
Adjuvant polyarthritis I: incorporation of quantitative measurements of humoral and cellular immune response.
Topics: Animals; Arthritis; Arthritis, Experimental; Azathioprine; Cell Line; Cyclophosphamide; Edema; Freun | 1977 |
A case of pulmonary veno-occlusive disease respondong to treatment with azathioprine.
Topics: Alopecia; Arthritis; Azathioprine; Female; Humans; Middle Aged; Pulmonary Veins; Raynaud Disease; Sk | 1977 |
[Treatment of psoriasis arthropathy with either azathioprine or methotrexate (author's transl)].
Topics: Adult; Arthritis; Azathioprine; Female; Humans; Male; Methotrexate; Middle Aged; Psoriasis | 1976 |
[Cytotoxic treatment of chronic joint diseases].
Topics: Adult; Arthritis; Arthritis, Rheumatoid; Azathioprine; Chronic Disease; Cyclophosphamide; Drug Evalu | 1976 |
Frontiers in inflammatory bowel disease. The proceedings of a conference sponsored by the McReynolds Foundation. Part II.
Topics: Adenocarcinoma; Arthritis; Azathioprine; Child; Chronic Disease; Colitis, Ulcerative; Colonic Neopla | 1975 |
Studies on the effects of pharmacological agents on antigen-induced arthritis in BALB/c mice.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antigens; Arthritis; Arthritis, Experimental; Azat | 1987 |
Serum osteocalcin in rheumatoid arthritis and other inflammatory arthritides: relation between inflammatory activity and the effect of glucocorticoids and remission inducing drugs.
Topics: Adrenocorticotropic Hormone; Adult; Aged; Arthritis; Arthritis, Rheumatoid; Azathioprine; Calcium-Bi | 1986 |
[An analysis of the morbid condition in adjuvant arthritic rats and a new method for evaluating anti-rheumatic drugs].
Topics: Animals; Arthritis; Arthritis, Experimental; Azathioprine; Drug Evaluation, Preclinical; Gold Sodium | 1988 |
Benign hypergammaglobulinemic purpura in a patient with ulcerative colitis and peripheric arthritis.
Topics: Adult; Arthritis; Azathioprine; Colitis, Ulcerative; Humans; Male; Prednisone; Purpura, Hyperglobuli | 1988 |
Adverse reactions to azathioprine mimicking gastroenteritis.
Topics: Adult; Arthritis; Azathioprine; Female; Gastroenteritis; Humans; Psoriasis | 1987 |
Abnormal calcium and magnesium stores in erythrocytes and granulocytes from patients with inflammatory connective tissue diseases. Relationship to inflammatory activity and effect of corticosteroid therapy.
Topics: Adrenal Cortex Hormones; Arthritis; Arthritis, Rheumatoid; Azathioprine; Calcium; Cyclophosphamide; | 1985 |
[Inhibition of immunologically induced inflammation by the plant steroid withaferin A].
Topics: Adjuvants, Immunologic; Animals; Arthritis; Azathioprine; Chick Embryo; Chickens; Cholestanes; Cyclo | 1973 |
Effect of predosing animals with immunosuppressive drugs on immune and non-immune induced inflammatory responses.
Topics: Adjuvants, Immunologic; Animals; Arthritis; Azathioprine; Carrageenan; Cyclophosphamide; Dexamethaso | 1974 |
Preliminary results of azathioprine treatment in severe rheumatic disease.
Topics: Adrenocorticotropic Hormone; Adult; Aged; Arthritis; Arthritis, Rheumatoid; Azathioprine; Blood Cell | 1969 |
Treatment of psoriatic arthropathy with either azathioprine or methotrexate.
Topics: Adult; Arthritis; Azathioprine; Female; Humans; Male; Methotrexate; Middle Aged; Psoriasis | 1974 |
[Reiter's disease in the female].
Topics: Adult; Arthritis; Arthritis, Reactive; Aspirin; Azathioprine; Biopsy; Female; Humans; Liver; Methylp | 1974 |
Some aspects of anti-inflammatory action of immunosuppressive drugs.
Topics: Adjuvants, Immunologic; Animals; Anti-Inflammatory Agents; Arthritis; Arthritis, Rheumatoid; Azathio | 1974 |
Radiation reversal of acute rejection in patients with life-threatening infections.
Topics: Adult; Antilymphocyte Serum; Arthritis; Azathioprine; Bacterial Infections; Cobalt Isotopes; Dose-Re | 1973 |
The effect of azathioprine on gammaglobulin synthesis in man.
Topics: Antibodies, Antinuclear; Arthritis; Arthritis, Rheumatoid; Azathioprine; Chromatography, DEAE-Cellul | 1972 |
The effect of immunosuppression on polyarthritis induced by Mycoplasma arthritidis in rats.
Topics: Animals; Arthritis; Azathioprine; Chlorambucil; Cyclophosphamide; Immune Sera; Immunosuppressive Age | 1973 |
Letter: Reaction to azathioprine.
Topics: Adult; Arthritis; Azathioprine; Fever; Humans; Liver Cirrhosis; Male | 1973 |
[Changes of mucopolysaccharase, protease and collagenolytic activities in rats with adjuvant arthritis and the effects of various anti-inflammatory drugs].
Topics: Animals; Anti-Inflammatory Agents; Arthritis; Azathioprine; Barbiturates; Chloroquine; Collagen; Cyc | 1973 |
Comparison of the effects of two cytotoxic drugs and of antilymphocytic serum on immune and non-immune inflammation in experimental animals.
Topics: Animals; Antilymphocyte Serum; Arthritis; Azathioprine; Cyclophosphamide; DNA Replication; Exudates | 1970 |
The influence of anti-inflammatory and immunosuppressant drugs on Nystatin induced oedema.
Topics: Animals; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Arthritis; Aspirin; Azathioprine; Ch | 1971 |
[Case report on the treatment with azathioprine of collagen diseases].
Topics: Adult; Arthritis; Autoimmune Diseases; Azathioprine; Chronic Disease; Collagen Diseases; Dermatomyos | 1971 |
A comparison of immunosuppressive and anti-inflammatory agents in the rat.
Topics: Animals; Anti-Inflammatory Agents; Antibody Formation; Antilymphocyte Serum; Arthritis; Azathioprine | 1971 |
[Long-term studies on indomethacin in rheumatology with special reference to its use in combination with azathioprine].
Topics: Administration, Oral; Arthritis; Arthritis, Rheumatoid; Azathioprine; Chronic Disease; Drug Combinat | 1971 |
The nature and treatment of psoriasis.
Topics: Adrenal Cortex Hormones; Antibodies, Antinuclear; Arthritis; Azathioprine; Diagnosis, Differential; | 1969 |
[Basic therapy of progressive chronic arthritis. 2].
Topics: Alkylating Agents; Antimetabolites; Antineoplastic Agents; Arthritis; Azathioprine; Chronic Disease; | 1970 |
[Immunosuppressive therapy with antimetabolites].
Topics: Adrenal Cortex Hormones; Antimetabolites; Arthritis; Azathioprine; Blood Sedimentation; Humans; Immu | 1967 |